Filtered By:
Condition: Cirrhosis
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 96 results found since Jan 2013.
Prevalence of hepatitis B infection in the Gambian population: A narrative review of recent developments
This study reviewed the recent trends in the epidemiological characteristics of HBV in the Gambia. The researchers conducted an online literature search for primary studies on HBV prevalence published in the past two decades from Jan 1992 to Feb 2022 inclusive on Google Scholar, PubMed, and Scopus. All retrieved studies were assessed for eligibility according to specific inclusion/exclusion criteria, data completeness, and methodological coherence. We found that HBV infection prevalence is above 8% in The Gambia. Moreover, HBV is the most common cause of hepatocellular carcinoma (HCC) in Gambia. Liver cirrhosis and HCC hav...
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Muhammed Camara Marcarious M Tantuoyir SeyedAhmad SeyedAlinaghi Fereshteh Ghiasvand Zahra Ahmadinejad Source Type: research
Analysis of hepatocellular carcinoma associated with hepatitis B virus
J Cell Mol Med. 2023 Jul 30. doi: 10.1111/jcmm.17867. Online ahead of print.ABSTRACTThe hepatitis B virus (HBV) is considered one of the main driving forces in the development of hepatocellular carcinoma (HCC). Human HBV is a partially double-stranded DNA (dsDNA) virus consisting of approximately 3.2 kbp. HBV predominantly infects hepatocytes via the receptor sodium taurocholate cotransporting polypeptide (NTCP) and coreceptor hepatic proteoglycan. The replication of HBV in hepatocytes leads to apoptosis while simultaneously leading to cirrhosis and cancer. Although the integration of dsDNA into the hepatocyte genome seems...
Source: J Cell Mol Med - July 30, 2023 Category: Molecular Biology Authors: Litao Zheng Source Type: research
Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus - World Health Organization African Region, 2016-2021
MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):782-787. doi: 10.15585/mmwr.mm7229a2.ABSTRACTChronic hepatitis B virus (HBV) infection is one of the leading causes of cirrhosis and liver cancer. In 2019, approximately 1.5 million persons newly acquired chronic HBV infection; among these, 990,000 (66%) were in the World Health Organization (WHO) African Region (AFR). Most chronic HBV infections are acquired through mother-to-child transmission (MTCT) or during early childhood, and approximately two thirds of these infections occur in AFR. In 2016, the World Health Assembly endorsed the goal of elimination of mother-to-child t...
Source: MMWR Morb Mortal Wkl... - July 20, 2023 Category: Epidemiology Authors: Hyacinte J Kabore Xi Li Mary M Alleman Casimir M Manzengo Mutale Mumba Joseph Biey Gilson Paluku Ado M Bwaka Benido Impouma Rania A Tohme Source Type: research
ABO blood types, but not Secretor or Lewis blood types, influence strength of antibody response to Hepatitis B vaccine in Black South African children
We examined 16 polymorphisms in the ABO, FUT2, and FUT3 genes and their related phenotypes for associations with strength of antibody response to HBV vaccine in Black South African infants. Anti-HBc and anti-HBs antibody levels were measured by CMIA assay 1-3 months after the last dose of HBV vaccine. Prior infection occurred in 8/207 individuals (3.86%) who were removed from further study. Of the remaining 199 individuals, 83.4% individuals were strong responders (anti-HBs ≥ 100 mIU/ml, median 973 mIU/ml), another 15.6% were weak responders (anti-HBs < 100 mIU/ml, median 50 mIU/ml) and 1% were non-responders (anti-HB...
Source: Vaccine - May 11, 2023 Category: Allergy & Immunology Authors: Adam Berry Daniel Kapelus Payal Singh Michelle Groome Debra de Assis Rosa Source Type: research
The challenge of the age of hepatitis C virus elimination: why is HCV vaccination necessary?
Orv Hetil. 2023 Mar 5;164(9):322-331. doi: 10.1556/650.2023.32737. Print 2023 Mar 5.ABSTRACTHepatitis C virus is a common cause of chronic liver disease, that may lead to cirrhosis, hepatocellular cancer and liver transplanation. The advent of highly efficacious direct-acting antivirals and their success in the treatment of hepatitis C virus infection, generated soon an optimism. Thus, the World Health Organization has adopted a global strategy of reducing the incidence of new hepatitis B and C virus infection by 90 % by 2030. However, it turned out, that this goal is not achievable by drug treatment alone without a vaccin...
Source: Orvosi Hetilap - March 5, 2023 Category: General Medicine Authors: Alajos P ár Source Type: research
